Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 15,000 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the completion of the sale, the director now directly owns 157,557 shares in the company, valued at approximately $14,143,891.89. This trade represents a 8.69 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Blueprint Medicines Price Performance

Shares of NASDAQ BPMC traded up $1.21 on Friday, hitting $90.14. The company’s stock had a trading volume of 1,266,828 shares, compared to its average volume of 690,804. The stock has a 50 day moving average of $92.45 and a 200-day moving average of $97.23. The company has a market capitalization of $5.73 billion, a price-to-earnings ratio of -42.72 and a beta of 0.59. Blueprint Medicines Co. has a 12-month low of $72.24 and a 12-month high of $121.90. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. The firm had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. Blueprint Medicines’s revenue was up 126.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.20) EPS. As a group, research analysts predict that Blueprint Medicines Co. will post -3.68 EPS for the current year.

Institutional Trading of Blueprint Medicines

Large investors have recently made changes to their positions in the stock. Quarry LP acquired a new stake in shares of Blueprint Medicines during the 3rd quarter worth about $32,000. Covestor Ltd boosted its position in Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 403 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Blueprint Medicines during the third quarter worth approximately $108,000. Van ECK Associates Corp raised its holdings in Blueprint Medicines by 13.3% in the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 131 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of Blueprint Medicines during the 3rd quarter worth $122,000.

Analyst Ratings Changes

BPMC has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, November 15th. JPMorgan Chase & Co. started coverage on shares of Blueprint Medicines in a research note on Thursday, November 14th. They set an “overweight” rating and a $126.00 price target on the stock. JMP Securities restated a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research note on Monday, December 9th. UBS Group started coverage on Blueprint Medicines in a research report on Thursday, October 24th. They set a “neutral” rating and a $88.00 target price on the stock. Finally, Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.11.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.